<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7727">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006341</url>
  </required_header>
  <id_info>
    <org_study_id>1160-0219</org_study_id>
    <nct_id>NCT03006341</nct_id>
  </id_info>
  <brief_title>Validation of Predictors of OAC Initiation Using EMR Data</brief_title>
  <official_title>Validation of Predictors for Oral Anticoagulant Medication Choice Using EMR Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objectives of this study are, first, to identify select clinical covariates from
      electronic medical records (EMR) that might be associated with initiation of oral
      anticoagulant medications (dabigatran or warfarin) in patients with non-valvular atrial
      fibrillation (NVAF) at risk for stroke; second, to quantify the association between
      EMR-based clinical characteristics and patterns of insurance claims; third, to assess the
      potential for unmeasured confounding in dabigatran vs warfarin comparative effectiveness and
      safety studies based on administrative claims databases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Obesity</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Smoking</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol consumption</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal renal function</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding history or predisposition</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal function (estimated GFR closest to index dispensing)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Creatinine (closest to index dispensing)</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal liver function</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of atrial fibrillation</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of adherence: non-adherent/adherent</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncontrolled Hypertension</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congestive Heart Failure</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prior Transient Ischemic Attack</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperlipidemia</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAS-BLED Score</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antiplatelets or Non-steroidal Anti-inflammatory Drugs</measure>
    <time_frame>within 1 month</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate</arm_group_label>
    <description>NVAF patients initiating dabigatran etexilate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <description>NVAF patients initiating warfarin</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a recorded diagnosis of atrial fibrillation without evidence of valvular
        etiology and at risk for stroke
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First dispensing of warfarin or dabigatran between October 2010 and December 2014

          -  Diagnosis of atrial fibrillation

          -  ≥ 12 months enrolment in the database preceding the date of the first dispensing

          -  Age ≥ 18

          -  CHA2DS2-VASc score ≥ 1

        Exclusion Criteria:

          -  Prior use of oral anticoagulation

          -  Evidence of valvular atrial fibrillation

          -  Missing or ambiguous age or sex information

          -  Patients with a nursing home stay during baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>December 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
